Form 4 for BEAM Beam Therapeutics Inc.
Accepted 2023-04-05 00:00:00 ET · period of report 2023-04-03 · accession 0000899243-23-010815 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-04-05 | 2023-04-03+ | BEAM | Burrell Terry-Ann | CFO | S - Sale | $29.74 | -4,640 | 47.1K | -9% | -$138.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-03 | S | D | 2,454 | $30.31 | 49,303 | D | — | — | (F2) Includes 480 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2023. |
| 2 | Common | Common Stock | 2023-04-04 | S | D | 2,186 | $29.09 | 47,117 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.79 to $29.10, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |